- Home
- ABUS vs GBLI Comparison
ABUS vs GBLI Comparison
Compare ABUS & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- GBLI
- Stock Information
- Founded
- ABUS 2005
- GBLI 2016
- Country
- ABUS United States
- GBLI United States
- Employees
- ABUS N/A
- GBLI N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- ABUS Health Care
- GBLI Finance
- Exchange
- ABUS Nasdaq
- GBLI Nasdaq
- Market Cap
- ABUS 592.8M
- GBLI 476.1M
- IPO Year
- ABUS N/A
- GBLI 2003
- Fundamental
- Price
- ABUS $3.24
- GBLI $28.93
- Analyst Decision
- ABUS Strong Buy
- GBLI
- Analyst Count
- ABUS 4
- GBLI 0
- Target Price
- ABUS $5.50
- GBLI N/A
- AVG Volume (30 Days)
- ABUS 1.3M
- GBLI 4.7K
- Earning Date
- ABUS 05-05-2025
- GBLI 05-07-2025
- Dividend Yield
- ABUS N/A
- GBLI 4.77%
- EPS Growth
- ABUS N/A
- GBLI 70.49
- EPS
- ABUS N/A
- GBLI 3.12
- Revenue
- ABUS $6,171,000.00
- GBLI $441,087,000.00
- Revenue This Year
- ABUS $14.57
- GBLI $8.70
- Revenue Next Year
- ABUS $15.84
- GBLI $14.56
- P/E Ratio
- ABUS N/A
- GBLI $9.41
- Revenue Growth
- ABUS N/A
- GBLI N/A
- 52 Week Low
- ABUS $2.63
- GBLI $28.75
- 52 Week High
- ABUS $4.72
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- ABUS 50.09
- GBLI 26.37
- Support Level
- ABUS $2.71
- GBLI $29.59
- Resistance Level
- ABUS $3.32
- GBLI $29.90
- Average True Range (ATR)
- ABUS 0.21
- GBLI 0.86
- MACD
- ABUS 0.00
- GBLI -0.14
- Stochastic Oscillator
- ABUS 63.86
- GBLI 3.03
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.